Seborrhoeic Dermatitis

Seborrhoeic dermatitis is the inflammatory condition behind most adult dandruff and much undiagnosed facial redness: erythematous patches with greasy or fine scale distributed where sebaceous glands cluster — scalp, eyebrows, glabella, nasolabial folds, ears, beard area, central chest, and body folds. Dandruff — scale without visible inflammation — is its mildest expression and touches roughly half of adults at some point; the fuller dermatitis affects several percent at any time, peaking in infancy (cradle cap), young adulthood and later life, with men overrepresented. In darker skin it commonly reads as hypopigmented, petaloid patches rather than redness — a presentation still underrecognised, contributing to underdiagnosis exactly where scalp disease burden (interacting with textured-hair washing frequency and styling) is often highest.

The accepted model is a three-part interaction: Malassezia yeasts — universal skin commensals that thrive on sebum — release fatty-acid byproducts as they feed; susceptible individuals mount an inflammatory, barrier-disrupting response to those byproducts; and sebum supplies the terrain, explaining the distribution and the life-stage peaks. It is not an infection in the contagious sense (everyone hosts Malassezia; only some react), not poor hygiene, and not dryness — the flaking of seb derm is inflammatory, and treating it with heavier oils can feed the yeast. Flares track stress, winter, illness and fatigue with remarkable reliability. Two associations carry real clinical weight: abrupt, severe or treatment-resistant seborrhoeic dermatitis is a recognised cutaneous marker of HIV (severity correlating with immunosuppression), and prevalence is markedly elevated in Parkinson's disease and some neurological conditions — occasionally preceding motor signs.

Because the yeast-sebum-immunity triangle is constitutional, treatment aims at durable control. The backbone is topical antifungal therapy: ketoconazole or ciclopirox shampoos for the scalp (lathered, left minutes, rinsed — technique matters more than brand), the same agents as creams or the shampoo-as-facewash trick for face and chest, with zinc pyrithione and selenium sulphide as maintenance alternatives. Flares add short courses of low-potency topical corticosteroids or, for steroid-sparing on the face, calcineurin inhibitors (tacrolimus, pimecrolimus). The pattern that fails is intermittent panic treatment; the pattern that works is maintenance — antifungal wash once or twice weekly indefinitely, escalated early at flare onset. Infantile cradle cap needs mostly reassurance, emollient loosening and time.

After decades of recycling the same antifungals and steroids, the field gained a genuinely new option: roflumilast 0.3% topical foam — a once-daily PDE4 inhibitor — was approved for seborrhoeic dermatitis (2023, US) on trial results showing roughly 80% of patients reaching clear or almost clear, usable across scalp, face and body without steroid time-limits. Alongside it sit practical refinements with less fanfare: recognition of the hypopigmented petaloid phenotype in darker skin; wash-frequency-adapted scalp regimens (antifungal contact therapy compatible with weekly washing and protective styles); and honest placement of the sprawling anti-dandruff cosmetic aisle — helpful for scale, irrelevant to inflammation. The pipeline's interest in the Malassezia-immunity axis suggests this decade will add more.

Seborrhoeic dermatitis runs a relapsing-remitting course measured in decades, and the counselling that prevents frustration is upfront honesty: it recurs, control is realistic, cure is not on offer, and recurrence signals biology rather than treatment failure. The quality-of-life tax is chronically underrated — visible facial scaling and shoulder flakes carry social weight, itch disturbs sleep, and the condition's association with stress runs both directions. Practical living rules: keep the maintenance wash going through clear spells; expect winter and stress flares and pre-empt them; photograph your own pattern to learn your earliest flare sign; and for facial disease, build a minimal, non-occlusive skincare routine — the barrier is irritable, and product churn is a common flare source. Severe, sudden or spreading disease is the cue for the HIV and neurological considerations above — worth one frank clinical conversation, not anxiety.

For dandruff: an antifungal shampoo (ketoconazole, ciclopirox, zinc pyrithione), lathered and left five minutes before rinsing, twice weekly until clear and weekly thereafter — indefinitely. For face and folds: the same antifungals as cream or wash, short steroid or calcineurin-inhibitor pulses for flares, and roflumilast foam where available and needed. For textured hair and protective styles: contact-time regimens fitted to your washing schedule work — ask rather than abandoning treatment. For infants: cradle cap resolves; oil, loosen, wait. See a clinician if disease is severe, sudden, spreading, or simply not yielding — both to escalate treatment and to think once about the associations. And permanently retire the two myths: it is not dirt, and it is not dryness.